The administration of riluzole, an approved drug for amyotrophic lateral sclerosis, suppressed the increase of glutamate concentration, the decrease of GLT-1 expression and the development of mechanical allodynia. The gene discussed is SLC1A2; the disease is amyotrophic lateral sclerosis.